Journal ArticleDOI
Glycated albumin and diabetes mellitus
Norihiro Furusyo,Jun Hayashi +1 more
TLDR
GA is a ketoamine formed via a non-enzymatic glycation reaction of serum albumin and it reflects mean glycemia over two to three weeks and is useful as part of a routine examination to screen for both diabetes and atherosclerosis.About:
This article is published in Biochimica et Biophysica Acta.The article was published on 2013-12-01. It has received 98 citations till now. The article focuses on the topics: Diabetes mellitus & Advanced glycation end-product.read more
Citations
More filters
Journal ArticleDOI
Human serum albumin, systemic inflammation, and cirrhosis
TL;DR: Human serum albumin (HSA) is one of the most frequent treatments in patients with decompensated cirrhosis, and its ability to bind lipopolysaccharide and other bacterial products, reactive oxygen species, nitric oxide and other nitrogen reactive species, and prostaglandins is an outstanding feature.
Journal ArticleDOI
Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases
Kohei Nagumo,Motohiko Tanaka,Victor Tuan Giam Chuang,Hiroko Setoyama,Hiroshi Watanabe,Naoyuki Yamada,Kazuyuki Kubota,Motoko Tanaka,Kazutaka Matsushita,Akira Yoshida,Hideaki Jinnouchi,Makoto Anraku,Daisuke Kadowaki,Yu Ishima,Yutaka Sasaki,Masaki Otagiri,Toru Maruyama +16 more
TL;DR: In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.
Journal ArticleDOI
Glycated albumin: a potential biomarker in diabetes.
TL;DR: The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels, which have ensured its laboratory characteristics have ensured the highlight of GA in studies from the last decade.
Journal ArticleDOI
Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population
Marijn M. Speeckaert,Wim Van Biesen,Joris R. Delanghe,Robbert Slingerland,Andrej Wiecek,James G. Heaf,Christiane Drechsler,Raluca Lacatus,Raymond Vanholder,Ionut Nistor +9 more
TL;DR: Although reference values of HbA1C might be different in patients with chronic kidney disease, it still remains the cornerstone as follow-up of longer term glycaemic control, as most clinical trials have used it as reference.
Journal ArticleDOI
Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231
Hana Sharaf,Sabine Matou-Nasri,Qiuyu Wang,Zaki Rabhan,Hamad Al-Eidi,Abdulkareem Al Abdulrahman,Nessar Ahmed +6 more
TL;DR: AGEs might contribute to breast cancer development and progression partially through the regulation of MMP-9 activity and RAGE signal activation and may represent promising targets for drug therapy to treat diabetic patients with breast cancer.
References
More filters
Journal Article
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
R C Turner,Rury R. Holman,Carole A. Cull,Irene M Stratton,David R Matthews,V Frighi,Susan E. Manley,Andrew Neil,K McElroy,D Wright,E. M. Kohner,Caroline S. Fox,D R Hadden,Z Mehta,Albert V. Smith,Z Nugent,Richard Peto,A I Adlel,Jim Mann,P A Bassett,S. Oakes,Tim Dornan,Stephen J Aldington,H Lipinski,R Collum,K Harrison,C MacIntyre,S Skinner,A Mortemore,D Nelson,S Cockley,S Levien,L Bodsworth,R Willox,T Biggs,S Dove,E Beattie,M Gradwell,S Staples,R Lam,F Taylor,L Leung,R D Carter,S M Brownlee,K E Fisher,K Islam,R. Jelfs,P A Williams,F A Williams,P J Sutton,A Ayres,Lisa Logie,C Lovatt,M A Evans,L A Stowell,I Ross,I A Kennedy,D. J. Croft,A H Keen,C Rose,M Raikou,A E Fletcher,Christopher J. Bulpitt,Clare Battersby,J S Yudkin,Richard Stevens,M R Stearn,S L Palmer,M S Hammersley,S L Franklin,R S Spivey,Jonathan C. Levy,C R Tidy,N J Bell,J Steemson,B A Barrow,R Coster,K Waring,L Nolan,E Truscott,N Walravens,L Cook,H Lampard,C Merle,P Parker,J McVittie,I Draisey,L E Murchison,Brunt Ahe.,M J Williams,D W Pearson,Petrie Xmp.,Lean Mej.,D Walmsley,F Lyall,E Christie,J Church,E Thomson,A Farrow,J M Stowers,M Stowers,K McHardy,N Patterson,Alex D. Wright,N A Levi,Shearer Aci.,Thompson Rjw.,G Taylor,S Rayton,M Bradbury,A Glover,A Smyth-Osbourne,C Parkes,J Graham,P England,S Gyde,C Eagle,B Chakrabarti,Josh Smith,J Sherwell,N. W. Oakley,M. Whitehead,G P Hollier,T. Pilkington,J Simpson,Michael W. Anderson,S Martin,J Kean,B Rice,A Rolland,J Nisbet,E M Kohner,A Dornhorst,M C Doddridge,M Dumskyij,S Walji,P Sharp,M Sleightholm,G Vanterpool,G Frost,M Roseblade,S Elliott,S Forrester,Meredith C. Foster,K Myers,R Chapman,J R Hayes,R W Henry,M S Featherston,Archbold Gpr.,M Copeland,R Harper,I Richardson,H A Davison,L Alexander,Scarpello Jhb.,D E Shiers,R J Tucker,Worthington Jrh.,S Angris,A Bates,J Walton,M Teasdale,J Browne,S Stanley,B A Davis,R C Strange,Hadden,L Kennedy,A B Atkinson,P M Bell,D R McCance,J Rutherford,A M Culbert,C Hegan,H Tennet,N Webb,I Robinson,J Holmes,S Nesbitt,A S Spathis,S Hyer,M E Nanson,L M James,J M Tyrell,C Davis,P Strugnell,M Booth,H Petrie,D Clark,S Hulland,J L Barron,B C Gould,J Singer,A Badenoch,M McGregor,L Isenberg,M Eckert,K Alibhai,E Marriot,Christopher E. Cox,R Price,M Fernandez,A Ryle,S Clarke,G Wallace,E Mehmed,J A Lankester,E Howard,A Waite,S MacFarlane,R H Greenwood,J Wilson,M J Denholm,R C Temple,K Whitfield,F Johnson,C Munroe,S Gorick,E Duckworth,M Fatman,S Rainbow,L J Borthwick,D J Wheatcroft,R J Seaman,R A Christie,W Wheatcroft,P Musk,Jennifer White,S McDougal,M Bond,P Raniga,J L Day,M J Doshi,James G. Wilson,J. Howard-Williams,H Humphreys,A Graham,K Hicks,S Hexman,P Bayliss,D Pledger,R W Newton,R T Jung,C Roxburgh,B Kilgallon,L Dick,N Waugh,S Kilby,A Ellingford,J Burns,C Fox,M C Holloway,H M Coghill,N Hein,A J Fox,W Cowan,M Richard,K Quested,S J Evans,Richard B Paisey,Brown Npr.,A J Tucker,R Paisey,F Garrett,J Hogg,P Park,K Williams,P Harvey,R Wilcocks,S Mason,J. C. Frost,C Warren,P Rocket,L Bower,J M Roland,D J Brown,J Youens,K Stanton-King,H Mungall,V Ball,W Maddison,D Donnelly,S King,P Griffin,Sidney C. Smith,S Church,Graham Dunn,Andrew D. Wilson,K Palmer,P M Brown,D Humphriss,Davidson Ajm.,Richard Rose,L Armistead,S Townsend,P Poon,Peacock Ida.,Culverwell Njc.,M H Charlton,Connolly Bps.,J Peacock,J Barrett,J Wain,W Beeston,George L. King,P G Hill,Boulton Ajm.,A M Robertson,V Katoulis,A Olukoga,H McDonald,S Kumar,F Abouaesha,B Abuaisha,E A Knowles,S Higgins,J Booker,J Sunter,K Breislin,R Parker,P Raval,J Curwell,H Davenport,G Shawcross,A Prest,J Grey,H Cole,C Sereviratne,R J Young,J R Clyne,M Gibson,I O'Connell,L M Wong,S J Wilson,K L Wright,Chris Wallace,D McDowell,A C Burden,E M Sellen,R Gregory,M Roshan,N Vaghela,M Burden,C Sherriff,S Mansingh,J Clarke,J Grenfell,Je Tooke,K. M. MacLeod,C Seamark,M Rammell,C Pym,J Stockman,C Yeo,J Piper,L Leighton,Ellen Green,M Hoyle,K Jones,A Hudson,A J James,Angela C. Shore,A Higham,B Martin,Neil Haw.,Butterfield Wjh.,Doll Wrs.,R Eastman,F R Ferris,N Kurinij,K McPherson,R F Mahler,Tom W. Meade,G Shafer,P J Watkins,H Keen,D Siegel,D J Betteridge,R D Cohen,D Currie,Julie L Darbyshire,J V Forrester,T Guppy,D G Johnston,Alistair McGuire,Mike Murphy,A M el-Nahas,B Pentecost,D Spiegelhalter,Alberti Kgmm.,R Denton,Philip Home,S Howell,Jarrett,V Marks,Michael Marmot,J D Ward,Grp Ukpds. +398 more
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal Article
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R C Turner,C Fox,Matthews,H McElroy,Carole A. Cull,Rury R. Holman,P. A. Neil,D R Hadden,D Wright,E Manley,Irene M Stratton,UK Prospective Diabetes,E M Kohner,Frighi,Michael Gnant +14 more
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
TL;DR: Elevated levels of CRP and IL-6 predict the development of type 2 DM, and data support a possible role for inflammation in diabetogenesis.
Journal ArticleDOI
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
Yasuo Ohkubo,Hideki Kishikawa,Eiichi Araki,Takao Miyata,S. Isami,S. Motoyoshi,Yujiro Kojima,Naohiko Furuyoshi,Motoaki Shichiri +8 more
TL;DR: In conclusion, intensive glycemic control by multiple insulin injection therapy can delay the onset and the progression of diabetic retinopathy, nephropathy and neuropathy in Japanese patients with NIDDM.
Journal ArticleDOI
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
David M. Nathan,Beverly Balkau,Enzo Bonora,Knut Borch-Johnsen,John B. Buse,Stephen Colagiuri,Mayer B. Davidson,Ralph A. DeFronzo,Saul Genuth,Rury R. Holman,Linong Ji,Sue Kirkman,William C. Knowler,Desmond A. Schatz,Jonathan E. Shaw,Eugene Sobngwi,Michael Steffes,Olga Vaccaro,Nicholas J. Wareham,Bernard Zinman,Richard Kahn +20 more
TL;DR: Kilpatrick et al. as mentioned in this paper discussed the limitations of the A1C assay for populations in which it is not available or is currently too expensive, as well as for individuals in whom the assay may be misleading.
Related Papers (5)
Clinical impact of glycated albumin as another glycemic control marker
Masafumi Koga,Soji Kasayama +1 more